Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation.

Publication Title

Cureus

Authors

Julie Dricken, Colon and Rectal Clinic, Swedish Cancer Institute, Seattle, USA.Follow
Erica Pettke, Colon and Rectal Clinic, Swedish Cancer Institute, Seattle, USA.Follow
John A Griffin, Colon and Rectal Clinic, Swedish Cancer Institute, Seattle, USA.Follow
Henry Y Li
Vivek Mehta, Department of Radiation Oncology, Swedish Cancer Institute, Seattle, USA.Follow

Document Type

Article

Publication Date

4-18-2020

Abstract

Capecitabine, a prodrug of fluorouracil, is a component of many chemotherapy regimens used to treat a wide variety of malignancies. One of the most common adverse reactions experienced by those who have been exposed to capecitabine is palmar-plantar erythrodysesthesia (PPE). PPE is a cutaneous manifestation of chemotherapy-related drug toxicity that has signs and symptoms of erythema, edema, pain, ulceration, or desquamation of the palms of the hands and soles of the feet. The signs and symptoms occur with varying severity. There are few reports of the genitalia being similarly affected. The following case describes a patient with locally advanced rectal cancer who experienced erythrodysesthesia secondary to a capecitabine-containing neoadjuvant chemoradiation regimen that primarily and most significantly involved the genitalia.

Clinical Institute

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Swedish Digestive Health Institute